Baroni C D, Uccini S, Ruco L, Soravito G
J Natl Cancer Inst. 1975 Sep;55(3):619-22. doi: 10.1093/jnci/55.3.619.
Charles River mice either untreated or treated at birth with 7,12-dimethylbenz]alpha[anthracene (DMBA) were given allogeneic spleen cells from adult C57BL/Cas donors. These spleen cells were given as a single injection to mice at birth or at 7 or 14 days of age. Allogeneic treatment of mice at birth significantly increased the incidence of DMBA-induced lymphomas and shortened the latency period of the tumors. The incidence of subcutaneous tumors was moderately increased in DMBA-treated mice given grafts of allogeneic cells at 7 days of age. Lung tumors appeared to be decreased in the group given DMBA at birth and allogeneic cells 14 days later. Treatment with only allogeneic cells gave results essentially similar to those observed in untreated controls.
对未处理的或出生时用7,12-二甲基苯并[a]蒽（DMBA）处理过的查尔斯河小鼠，给予成年C57BL/Cas供体的同种异体脾细胞。这些脾细胞在小鼠出生时、7日龄或14日龄时单次注射给药。出生时对小鼠进行同种异体处理显著增加了DMBA诱导的淋巴瘤的发生率，并缩短了肿瘤的潜伏期。在7日龄给予同种异体细胞移植的DMBA处理小鼠中，皮下肿瘤的发生率适度增加。出生时给予DMBA且14天后给予同种异体细胞的组中，肺肿瘤似乎减少。仅用同种异体细胞处理得到的结果与未处理对照组中观察到的结果基本相似。
